Dorling, Anthony - professor of transplant inflammation and repair


Consultant profiles


Tel: 020 7188 5880

Secretary: Jenny Owen/Irene Miles
Secretary tel: 020 7188 5667

  • Biography

    Professor Anthony Dorling qualified in medicine from the University of London in 1987, did general medical training in hospitals around the south east of England and gained membership of the Royal College of Physicians in 1990.

    He did his PhD under the supervision of Robert Lechler at the Royal Postgraduate Medical School, before embarking on specialist training in nephrology in 1995.

    Professor Dorling was appointed senior lecturer in immunology at Imperial College and honorary consultant nephrologist at the Hammersmith Hospital in 2001, becoming a Reader in 2005. He was awarded fellowship of the Royal College of Physicians in the same year.

    In October 2009, Professor Dorling was appointed to a personal Chair in Transplant Inflammation and Repair at King’s College London, based at Guy’s Hospital.

    He is head of the Innate Immunity Section of the Division of Transplant Immunology and Mucosal Biology at King's College London, sits on the Renal Project Board Steering Committee and CAG Executive Committee and chairs the Transplant Strategy Group.

  • Specialist interests

    • optimising transplant survival
    • chronic rejection of kidney allografts
    • antibody-incompatible renal transplantation.
  • Research interests

    In the last five years, Professor Dorling’s focus has been the humoral, cellular and molecular mechanisms involved in transplant rejection. Clinically, he has been working in two main areas:

    1. antibody-incompatible transplants, attempting to understand ‘accommodation’
    2. chronic rejection – using an observational study, two randomised controlled clinical trials (RituxiCAN-C4 and OuTSMART) and a new virtual clinic (optimising transplant survival clinic) he has been collecting cohorts of patients in different stages of chronic antibody-mediated rejection.

    These studies are expected to provide valuable insights into disease pathogenesis

    Professor Dorling's laboratory work is focused on the role clotting proteins play in inflammatory vascular disease. He has shown that inhibiting coagulation protease activation within transplanted organs has a significant impact on rejection, mostly by preventing thrombin-mediated signalling through protease activated receptors, which is required to establish tissue chemokine gradients to initiate leukocyte recruitment into organs.

    Professor Dorling has also demonstrated the importance of protease activated receptor signalling on mobilized CD34+ cells in chronic rejection. This has led to a pilot observational study in humans (VASPECKT), which has just finished collecting data.

  • Publications

    Selected publications over last six years:

    1. D. Chen, L. Ma, E-L Tham, S. Maresh, R. I. Lechler, J. H. McVey, A. Dorling. Fibrocytes mediate intimal hyperplasia post-vascular injury and are regulated by two tissue factor-dependent mechanisms. J Thromb Haemost. 2013 11 (5) 963-974.
    2. D. Armstrong-James, I. Teo, S. Herbst, M. Petrou, K.Y. Shiu, A. MacLean, D. Taube, A. Dorling and S. Shaunak. Renal allograft recipients fail to increase interferon gamma during invasive fungal diseases. Amer J. Transplant. 2012 12 (12) 3437-40.
    3. A. Dorling. Transplant Accommodation – Are the lessons learned from xenotransplantation pertinent for clinical allotransplantation? Amer J Transpl 2012 12(3) 545-53.
    4. D. Chen, S. Shrivastava, L. Ma, E-L. Tham, J. Abrahams, J. D. Coe, D. Scott, R. I. Lechler, J. H. McVey, A. Dorling. Inhibition of thrombin receptor signalling on a-smooth muscle actin+ CD34+ progenitors leads to repair after murine immune vascular injury. ATVB. 2012 32 (1): 43-49.
    5. K Chan, D Taube ,J Galliford, C Roufosse, T Cook, D Goodall, T Cairns, N Duncan, N Hakim, A Palmer, P Brookes, M Willicombe, A Warrens, A. Dorling, V Papalois, AG McLean. ‘Kidney transplantation with minimized maintenance: Alemtuzumab induction with Tacrolimus monotherapy; an open label, randomized trial’ Transplantation 2011 92 (7) 774-80.
    6. Willicombe, M. Roufosse, C. Brookes, P. Galliford, J. McLean, A. Dorling, A. Warrens, A. Cook, T. Cairns, T. Taube, D. ‘Antibody mediated rejection following alemtuzumab induction: incidence, risk factors and predictors of poor outcome.’ Transplantation 2011 92 (2) 176-82
    7. M. Willicombe, P. Brookes, E. Santos-Nunez, J. Galliford, A. Ballow, A. Mclean, C. Roufosse, H.T.Cook, A. Dorling, A.N. Warrens, T. Cairns and D. Taube. Outcome of Patients with Preformed Donor-Specific Antibodies Following Alemtuzumab Induction and Tacrolimus Monotherapy AJT 2011 11 (3):470-7.
    8. Karen Stevenson, Daxin Chen, Alan MacIntyre Liane M McGlynn , Paul Montague, Rawiya Charif, Murali Subramaniam, W.D. George, Anthony P. Payne, R. Wayne Davies, Anthony Dorling and Paul G. Shiels. Pancreatic Derived Pathfinder cells enable regeneration of critically damaged adult pancreatic tissue and completely reverse streptozotocin induced diabetes. Rejuvenation Research 2011. Apr;14(2):163-71.
    9. Marc Jevon, Tahera I Ansari, Jonathan Finch, Mustafa Zakkar, Paul C.Evans, Sandra Shurey, Paul D Sibbons, Phillip Hornick, Dorian O. Haskard, Anthony Dorling. Smooth muscle cells in porcine vein graft intimal hyperplasia are derived from the local vessel wall. Cardiovascular Pathology. May-Jun;20(3):e91-4.
    10. Armstrong-James D, Teo IA, Shrivastava S, Petrou MA, Taube D, Dorling A & Shaunak S. Exogenous interferon-g immuno-therapy for invasive fungal infections in kidney transplant patients. Am J Transplant. 2010. 10 (8) 1796-1803.
    11. Helen M Clarke, Seema Shrivastava, Roberto Motterlini, Philip Sawle, Daxin Chen, Anthony Dorling. Donor HO-1 expression inhibits intimal hyperplasia in unmanipulated graft recipients: a potential role for CD8+ T-cell modulation by carbon monoxide Transplantation 2009 88(5) 653-66.
    12. Galliford J, Charif R, Chan KK, Loucaidou M, Cairns T, Cook HT, Dorling A, Hakim N, McLean A, Papalois V, Taube D. ABO incompatible living renal transplantation with a steroid sparing protocol. Transplantation 2008 86 (7) 901-16.
    13. Chen D; Carpenter A; Abrahams J; Chambers RC; Lechler RI; McVey JH; Dorling A. Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med. 2008 205 (8) 1739-46.
    14. Chen D; Abrahams JM; Smith LM; McVey JH; Lechler RI; Dorling A. Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34+ vascular progenitors. Blood 2008 111 4155-4164.
    15. D. Chen, M. Weber, P.G. Shiels, R. Dong,Z. Webster, J. H. McVey, G. Kemball-Cook, E. G. D. Tuddenham, R. I. Lechler and A. Dorling. ‘Post-injury vascular intimal hyperplasia in mice is completely inhibited by CD34+ bone marrow-derived progenitor cells expressing membrane-tethered anticoagulant fusion proteins.’ J Thromb Haemost 2006 4 (10) 2191-98 (10) 2191-98.
    16. Rhys C. Roberts, Catherine Lane, Peter Hatfield, Elaine Clutterbuck, Mark Atkins, Ashley Brown and Anthony Dorling. ‘All anti-HBc-positive, HBsAg-negative dialysis patients on the transplant waiting list should be regarded as at risk of hepatitis B reactivation post-renal transplantation – report of three cases from a single centre.’ Nephrology Dialysis and Transplantation 2006 21 (11) 3316-9. (11) 3316-9.
    17. Summers, SA. Dorling, A. Boyle, J. Shaunak, S. ‘Cure of disseminated cryptococcal infection in a renal allograft recipient after the addition of interferon-g to antifungal therapy’ Am J Transpl 2005 5 (8) 2067-69.